The Filing Desk

Arcutis Biotherapeutics vs CorMedix

Arcutis Biotherapeutics ARQT · CorMedix CRMD · Pharmaceuticals

Arcutis Biotherapeutics reported revenue of $376 million in fiscal 2025, 1.2 times CorMedix's $312 million in fiscal 2025. Arcutis Biotherapeutics' revenue grew 91.3% in its latest year, and CorMedix's grew 617.0%. Arcutis Biotherapeutics had an operating margin of -3.2%, against 48.2% at CorMedix. Free cash flow was −$6 million at Arcutis Biotherapeutics and $173 million at CorMedix.

Side by side

Arcutis BiotherapeuticsCorMedix
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$376M$312M
Revenue growth91.3%617.0%
Revenue growth a year, last 5 years—335.1%
Gross margin90.2%88.5%
Operating margin−3.2%48.2%
Net margin−4.3%52.3%
Free cash flow−$6M$173M
Free cash flow margin−1.7%55.4%
Return on capital−16.9%—
Net debt to EBITDA—−0.9x
Dividends and buybacks$0M$0M
Change in diluted share count5.2%36.4%
Last close$28.26$4.66
P/E at the last close134.6×7.8×
Insider trades, last 12 monthssold $12.2 million—
Piotroski F-score4 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arcutis BiotherapeuticsCorMedix
Operating margin
Percent of revenue
Arcutis BiotherapeuticsCorMedix
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcutis BiotherapeuticsCorMedix

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcutis Biotherapeutics and CorMedix pages.